Early evaluation using a radiomic signature of unresectable hepatic metastases to predict outcome in patients with colorectal cancer treated with FOLFIRI and bevacizumab

Nom du journal : Gut

Année : 2019

Volume : doi: 10.1136/gutjnl-2018-316407 [Epub ahead of print]

Auteurs: Suc E, Ben Abdelghani M, Reinhold C, Phelip JM, Barbier E, Taïeb J, Lepage C, Ghiringhelli F, Gallix B, Khemissa-Akouz F, Desseigne F, Faroux R, Bouché O, Boige V, Texereau P, Bennouna J, François E, Seitz JF, Borel C, Dohan A, Guiu B, Le Malicot K, Soyer P, Jacquot S, Genet D, Jouve JL, Rinaldi Y, Aparico T, Hoeffel C, PRODIGE 9 Investigators and PRODIGE 20 Investigators,